Perinatal viral hepatitis C and performance capabilities for its therapy

Abstract

The aim of the study: to establish the rate of the vertical transmission of HCV infection and justify the usefulness of the drug a-IFN2b (Viferon®) in children with perinatal infection with hepatitis C virus (HCV) at the early stages of the disease. There were examined 465 children aged 2.5 months to 3 years old (at the time of the enrollment in the study), born to mothers with HCV infection and the frequency of transmission from mother to child was established to be is 7.1% (33 cases). In 54.5% the genotype 1b was recorded, in 3% - 1a, and in 6.0 % - 2 genotype. Viferon® drug in doses of 3х10 6IU/m 2 was introduced to 17 infants aged from 3 to 12 months (duration of the course: 6 months in cases with 3, 2 genotype and 12 months - in patients with genotype 1). The efficacy of therapy was 58.8 % (RNA HCV (-) 10 cases. In prescription the drug to children under 6 months the efficacy was 62.5%, under 6-12 months - 44.4%. In the control group (16patients) spontaneous viral clearance was established to be in 18.7% of cases. The medication did not cause adverse effects and was well tolerated by children. In none out of the 17 children treated with the drug Viferon®, we have not reported adverse events (clinical symptoms, abnormalities in the hemogram and biochemical indices). The obtained data confirm the expediency of the early use of antiviral drug Viferon® in the treatment of children with perinatal HCV. Nо significant difference in the efficacy of therapy in different genotypes of the virus was identified. Virtually in all children (9 out of 10 children) responded to Viferon® therapy, there was noted Sustained Viral Response

Keywords

viral hepatitis C / children / perinatal infection / therapy / suppositories a-IFN2b (Viferon®)

References

[1] Доклад ВОЗ «Вирусные гепатиты»: 63-я сессия Всемирной Ассамблеи Здравоохранения, 25.03.2010.

[2] Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины: Пер. с англ. М.: Медиа Сфера; 1998.

[3] Малиновская В.В., Холодняк Г.Е., Московская И.А., Рыбакова Н.В., Трифонова Р.С. Алгоритм профилактики вертикальной трансмиссии и реализации перинатальной инфекции вирусов гепатита С и В. Лечащий врач. 2011; 2.

[4] Сенягина Н.Е., Лаврова А.Е., Зорин В.В., Галова Е.А. Факторы риска перинатальной передачи вирусного гепатита С. Медицинский альманах. 2011; 4 (17): 34--6.

[5] Чередниченко Т.В., Московская И.В. Вирусный гепатит у детей первого года жизни. Детские инфекции. 2003; 3: 11^^.

[6] Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М.: ГОУ ВУНМЦ Мз РФ; 2003.

[7] Al Ali J., Owayed S., Al-Qabandi W. et al. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann. Hepatol. 2010; 9: 156-60.

[8] American Academy of Pediatrics. Hepatitis C. In: Pickering L.K., Baker C.J., Long S.S., McMillan J.A., eds. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006: 355-9.

[9] Bortolotti F., Iorio R., Resti M. et al. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J. Hepatol. 2007; 46: 783-90.

[10] Bortolotti F., Verucchi G., Camma C. et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008; 134: 1900-7.

[11] Bortolotti F., Indolfi G., Zancan L. et al. Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades. Dig. Liver Dis. 2011; 43: 325-9.

[12] Davies G., Wilson R., Desilets V. et al. Amniocentesis and women with hepatitis B, hepatitis C, or human immunodeficiency virus. J. Obstet. Gynaecol. Can. 2003; 25: 145-52.

[13] Di Marco V. Chronic hepatitis C in children is a mild and curable liver disease. Dig. Liver Dis. 2011; 43: 266-7.

[14] European Pediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin. Infect. Dis. 2005; 41: 45-51.

[15] Guido M., Bortolotti F. Viral hepatitis: Treating hepatitis C in children: an open horizon. Nature Rev. Gastroenterol. Hepatol. 2011; 8: 247-8.

[16] Iorio R., Giannattasio A., Sepe A. et al. Chronic hepatitis C in childhood: an 18-year experience. Clin. Infect. Dis. 2005; 41: 1431-7.

[17] Jafri W., Jafri N., Yakoob J. et al. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect. Dis. 2006; 6: 101-9.

[18] Locasciulli A., Gornati G., Tagger A. et al. Hepatitis C virus infection and chronic liver disease in children with leukemia in long-term remission. Blood. 1991; 78: 1619-22.

[19] Mast E.E., Hwang L.-Y., Seto D.S.Y. et al. Risk factors for perinatal transmission of hepatitis C virus and the natural history of HCV infection acquired in infancy. J. Infect. Dis. 2005; 192: 1880-9.

[20] Mohamed M.K., Magder L.S., Abdel-Hamid M. et al. Transmission of hepatitis C virus between parents and children. Am. J. Trop. Med. Hyg. 2006; 75: 16-20.

[21] Murray K.F., Richardson L.P., Morishima C. et al. Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics. 2003; 111: 153-7.

[22] Nelson S.P., Jonas M.M. Hepatitis C infection in children who received extracorporeal membrane oxygenation. J. Pediatr. Surg. 1996; 31: 644-8.

[23] Vogt M., Lang T., Frosner G. et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N. Engl. J. Med. 1999; 341: 866-70.

RIGHTS & PERMISSIONS

Eco-vector